FDA Releases Final Industry Guidelines for CAR-T Cell Therapy
- Normal Liver Cells Found to Promote Cancer Metastasis to the Liver
- Nearly 80% Complete Remission: Breakthrough in ADC Anti-Tumor Treatment
- Vaccination Against Common Diseases May Prevent Dementia!
- New Alzheimer’s Disease (AD) Diagnosis and Staging Criteria
- Breakthrough in Alzheimer’s Disease: New Nasal Spray Halts Cognitive Decline by Targeting Toxic Protein
- Can the Tap Water at the Paris Olympics be Drunk Directly?
FDA Releases Final Industry Guidelines for CAR-T Cell Therapy
- Should China be held legally responsible for the US’s $18 trillion COVID losses?
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA Releases Final Industry Guidelines for CAR-T Cell Therapy
On January 29th, the FDA issued the final industry guidelines for the development and considerations of CAR-T cell therapy products. This update builds upon the draft released in March 2022, incorporating feedback and input from stakeholders to form the ultimate guidance.
The guidelines provide specific recommendations on chemistry, manufacturing, and controls, pharmacology and toxicology, as well as clinical study design and comparability studies for CAR-T cell products. (For further details, refer to previous articles on Dingxiangyuan: FDA Update: All Marketed CAR-T Therapies to Include Black Box Warning)
While the focus of this guidance is on CAR-T cell products, the FDA emphasizes that much of the information and recommendations are also applicable to other genetically modified lymphocyte products, such as CAR-NK or TCR-T. Additionally, attention is drawn to the need for ongoing monitoring of the persistence and long-term follow-up of CAR-T cells in clinical settings.
(Image and information source: FDA)
Related News:
FDA has mandated a top-level black box warning for all marketed CAR-T therapies
Potential Secondary Tumors Linked to CAR-T Cancer Therapy?
Low Probability of Secondary T-Cell Malignancies After CAR-T Therapy
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.